Showing 6,301 - 6,320 results of 17,945 for search 'significantly ((a decrease) OR (larger decrease))', query time: 0.30s Refine Results
  1. 6301

    Changes in the platelet count. by Lu Yang (30847)

    Published 2025
    “…</p><p>Methods</p><p>This is a single-center, prospective, randomized controlled study conducted from June 1, 2021, to October 31, 2022 on patients diagnosed with locally advanced NPC. …”
  2. 6302

    Changes in the white blood cell count. by Lu Yang (30847)

    Published 2025
    “…</p><p>Methods</p><p>This is a single-center, prospective, randomized controlled study conducted from June 1, 2021, to October 31, 2022 on patients diagnosed with locally advanced NPC. …”
  3. 6303

    Changes in the hemoglobin. by Lu Yang (30847)

    Published 2025
    “…</p><p>Methods</p><p>This is a single-center, prospective, randomized controlled study conducted from June 1, 2021, to October 31, 2022 on patients diagnosed with locally advanced NPC. …”
  4. 6304

    WBC and ANC on day 7 post-chemotherapy. by Lu Yang (30847)

    Published 2025
    “…</p><p>Methods</p><p>This is a single-center, prospective, randomized controlled study conducted from June 1, 2021, to October 31, 2022 on patients diagnosed with locally advanced NPC. …”
  5. 6305

    General clinical data of 88 patients with NPC. by Lu Yang (30847)

    Published 2025
    “…</p><p>Methods</p><p>This is a single-center, prospective, randomized controlled study conducted from June 1, 2021, to October 31, 2022 on patients diagnosed with locally advanced NPC. …”
  6. 6306

    CONSORT participant flow diagram. by Lu Yang (30847)

    Published 2025
    “…</p><p>Methods</p><p>This is a single-center, prospective, randomized controlled study conducted from June 1, 2021, to October 31, 2022 on patients diagnosed with locally advanced NPC. …”
  7. 6307

    S4 File - by Lu Yang (30847)

    Published 2025
    “…</p><p>Methods</p><p>This is a single-center, prospective, randomized controlled study conducted from June 1, 2021, to October 31, 2022 on patients diagnosed with locally advanced NPC. …”
  8. 6308

    Data Sheet 6_A genome-wide shRNA screen uncovers a novel potential ligand for NK cell activating receptors.pdf by Paolo Romania (399007)

    Published 2025
    “…PLAC1 and DSG2 expression in healthy tissues and NK cells was obtained from the HPA database and a GEO dataset.</p>Results<p>We identified ten candidate genes whose downregulation in K562 cells decreased NK cell-mediated cytotoxicity to levels comparable to silencing the MICA gene. …”
  9. 6309

    Data Sheet 4_A genome-wide shRNA screen uncovers a novel potential ligand for NK cell activating receptors.pdf by Paolo Romania (399007)

    Published 2025
    “…PLAC1 and DSG2 expression in healthy tissues and NK cells was obtained from the HPA database and a GEO dataset.</p>Results<p>We identified ten candidate genes whose downregulation in K562 cells decreased NK cell-mediated cytotoxicity to levels comparable to silencing the MICA gene. …”
  10. 6310

    Data Sheet 3_A genome-wide shRNA screen uncovers a novel potential ligand for NK cell activating receptors.pdf by Paolo Romania (399007)

    Published 2025
    “…PLAC1 and DSG2 expression in healthy tissues and NK cells was obtained from the HPA database and a GEO dataset.</p>Results<p>We identified ten candidate genes whose downregulation in K562 cells decreased NK cell-mediated cytotoxicity to levels comparable to silencing the MICA gene. …”
  11. 6311

    Data Sheet 5_A genome-wide shRNA screen uncovers a novel potential ligand for NK cell activating receptors.pdf by Paolo Romania (399007)

    Published 2025
    “…PLAC1 and DSG2 expression in healthy tissues and NK cells was obtained from the HPA database and a GEO dataset.</p>Results<p>We identified ten candidate genes whose downregulation in K562 cells decreased NK cell-mediated cytotoxicity to levels comparable to silencing the MICA gene. …”
  12. 6312
  13. 6313
  14. 6314

    Discovery of Tamsulosin Derivatives with Shifted Selectivity from the α<sub>1</sub>‑Adrenergic Receptor to ANO1 as Potent Antiosteoporotic Agents by Chaoquan Tian (21009122)

    Published 2025
    “…The potency of compound <b>10</b> against ANO1 was comparable to that of <b>Tam</b> (IC<sub>50</sub>: 4.57 vs 7.22 μM), but its selectivity over α<sub>1</sub>-AR was significantly improved. Compared with <b>Tam</b>, the potency of compound <b>10</b> against α<sub>1A</sub>-, α<sub>1B</sub>-, and α<sub>1D</sub>-AR decreased by 118-fold, 642-fold, and 10,000-fold, respectively. …”
  15. 6315

    Discovery of Tamsulosin Derivatives with Shifted Selectivity from the α<sub>1</sub>‑Adrenergic Receptor to ANO1 as Potent Antiosteoporotic Agents by Chaoquan Tian (21009122)

    Published 2025
    “…The potency of compound <b>10</b> against ANO1 was comparable to that of <b>Tam</b> (IC<sub>50</sub>: 4.57 vs 7.22 μM), but its selectivity over α<sub>1</sub>-AR was significantly improved. Compared with <b>Tam</b>, the potency of compound <b>10</b> against α<sub>1A</sub>-, α<sub>1B</sub>-, and α<sub>1D</sub>-AR decreased by 118-fold, 642-fold, and 10,000-fold, respectively. …”
  16. 6316

    Discovery of Tamsulosin Derivatives with Shifted Selectivity from the α<sub>1</sub>‑Adrenergic Receptor to ANO1 as Potent Antiosteoporotic Agents by Chaoquan Tian (21009122)

    Published 2025
    “…The potency of compound <b>10</b> against ANO1 was comparable to that of <b>Tam</b> (IC<sub>50</sub>: 4.57 vs 7.22 μM), but its selectivity over α<sub>1</sub>-AR was significantly improved. Compared with <b>Tam</b>, the potency of compound <b>10</b> against α<sub>1A</sub>-, α<sub>1B</sub>-, and α<sub>1D</sub>-AR decreased by 118-fold, 642-fold, and 10,000-fold, respectively. …”
  17. 6317
  18. 6318
  19. 6319
  20. 6320